908 DEVICES INC. Selling, General and Administrative Expense
908 DEVICES INC. (MASS) reported Selling, General and Administrative Expense of $11.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-11
- 908 DEVICES INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $11.11M, a 7.50% increase year-over-year.
- 908 DEVICES INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $9.91M, a 3.17% decline year-over-year.
- 908 DEVICES INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $8.82M, a 15.73% decline year-over-year.
- 908 DEVICES INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $9.13M, a 5.69% decline year-over-year.
- 908 DEVICES INC. selling, general and administrative expense for fiscal 2025 was $38.53M, a 2.37% decline from fiscal 2024.
- 908 DEVICES INC. selling, general and administrative expense for fiscal 2024 was $39.46M, a 14.34% decline from fiscal 2023.
- 908 DEVICES INC. selling, general and administrative expense for fiscal 2023 was $46.07M, a 4.99% increase from fiscal 2022.
- 908 DEVICES INC. selling, general and administrative expense for fiscal 2022 was $43.88M, a 36.12% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.11M 10-Q · filed 2026-08-11 | $21.03M 10-Q · filed 2026-08-11 | $29.84M derived: sum of 3 quarters · filed 2026-08-11 | $38.98M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | $9.91M 10-Q · filed 2026-05-06 | $18.73M derived: sum of 2 quarters · filed 2026-05-06 | $27.86M derived: sum of 3 quarters · filed 2026-05-06 | $38.20M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $17.95M derived: sum of 2 quarters · filed 2026-03-09 | $28.29M derived: sum of 3 quarters · filed 2026-08-11 | $38.53M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $9.13M 10-Q · filed 2025-11-10 | $19.47M derived: sum of 2 quarters · filed 2026-08-11 | $29.71M 10-Q · filed 2025-11-10 | $40.17M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | $10.34M 10-Q · filed 2026-08-11 | $20.58M 10-Q · filed 2026-08-11 | $31.04M derived: sum of 3 quarters · filed 2026-08-11 | $40.72M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-03-31 | $10.24M 10-Q · filed 2026-05-06 | $20.70M derived: sum of 2 quarters · filed 2026-05-06 | $30.39M derived: sum of 3 quarters · filed 2026-05-06 | $41.49M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $20.15M derived: sum of 2 quarters · filed 2026-03-09 | $31.26M derived: sum of 3 quarters · filed 2026-03-09 | $39.46M 10-K · filed 2026-03-09 | $53.64M 10-K · filed 2025-03-07 | |||
| 2024-09-30 | $9.69M 10-Q · filed 2025-11-10 | $13.38M 10-Q · filed 2024-11-12 | $20.80M derived: sum of 2 quarters · filed 2025-11-10 | $29.00M 10-Q · filed 2025-11-10 | $39.88M 10-Q · filed 2024-11-12 | $40.77M derived: sum of 4 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $11.11M 10-Q · filed 2025-08-05 | $14.60M 10-Q · filed 2024-08-06 | $19.32M 10-Q · filed 2025-08-05 | $26.50M 10-Q · filed 2024-08-06 | $31.09M derived: sum of 3 quarters · filed 2025-08-05 | $42.41M derived: sum of 4 quarters · filed 2025-08-05 | ||
| 2024-03-31 | $8.21M 10-Q · filed 2025-05-13 | $11.90M 10-Q · filed 2024-05-03 | $19.98M derived: sum of 2 quarters · filed 2025-05-13 | $31.30M derived: sum of 3 quarters · filed 2025-05-13 | $42.50M derived: sum of 4 quarters · filed 2025-05-13 | |||
| 2023-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $23.09M derived: sum of 2 quarters · filed 2025-03-07 | $34.30M derived: sum of 3 quarters · filed 2025-03-07 | $46.07M 10-K · filed 2025-03-07 | $46.18M 10-K · filed 2024-03-08 | |||
| 2023-09-30 | $11.32M 10-Q · filed 2024-11-12 | $11.42M 10-Q · filed 2023-11-07 | $22.52M derived: sum of 2 quarters · filed 2024-11-12 | $34.30M 10-Q · filed 2024-11-12 | $34.63M 10-Q · filed 2023-11-07 | $46.13M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $11.21M 10-Q · filed 2024-08-06 | $23.21M 10-Q · filed 2024-08-06 | $34.81M derived: sum of 3 quarters · filed 2024-08-06 | $46.63M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | $12.00M 10-Q · filed 2024-05-03 | $23.60M derived: sum of 2 quarters · filed 2024-05-03 | $35.43M derived: sum of 3 quarters · filed 2024-05-03 | $46.14M derived: sum of 4 quarters · filed 2024-05-03 | ||||
| 2022-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $23.42M derived: sum of 2 quarters · filed 2024-03-08 | $34.13M derived: sum of 3 quarters · filed 2024-03-08 | $43.88M 10-K · filed 2024-03-08 | ||||
| 2022-09-30 | $11.83M 10-Q · filed 2023-11-07 | $22.54M derived: sum of 2 quarters · filed 2023-11-07 | $32.28M 10-Q · filed 2023-11-07 | $41.20M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $10.71M 10-Q · filed 2023-08-08 | $20.45M 10-Q · filed 2023-08-08 | $29.37M derived: sum of 3 quarters · filed 2023-08-08 | $38.16M derived: sum of 4 quarters · filed 2023-08-08 | ||||
| 2022-03-31 | $9.74M 10-Q · filed 2023-05-09 | $18.66M derived: sum of 2 quarters · filed 2023-05-09 | $27.45M derived: sum of 3 quarters · filed 2023-05-09 | $36.23M derived: sum of 4 quarters · filed 2023-05-09 | ||||
| 2021-12-31 | $8.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $17.70M derived: sum of 2 quarters · filed 2023-03-15 | $26.48M derived: sum of 3 quarters · filed 2023-03-15 | $32.23M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $8.79M 10-Q · filed 2022-11-14 | $17.57M derived: sum of 2 quarters · filed 2022-11-14 | $23.32M 10-Q · filed 2022-11-14 | $27.50M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $8.78M 10-Q · filed 2022-08-09 | $14.53M 10-Q · filed 2022-08-09 | $18.71M derived: sum of 3 quarters · filed 2022-08-09 | $21.89M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $5.75M 10-Q · filed 2022-05-10 | $9.94M derived: sum of 2 quarters · filed 2022-05-10 | $13.11M derived: sum of 3 quarters · filed 2022-05-10 | $15.55M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $7.36M derived: sum of 2 quarters · filed 2022-03-11 | $9.80M derived: sum of 3 quarters · filed 2022-03-11 | $12.50M 10-K · filed 2022-03-11 | ||||
| 2020-09-30 | $3.18M 10-Q · filed 2021-11-04 | $5.61M derived: sum of 2 quarters · filed 2021-11-04 | $8.32M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $2.44M 10-Q · filed 2021-08-04 | $5.14M 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | $2.71M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |